Exploring the significance of microbiota metabolites in rheumatoid arthritis: uncovering their contribution from disease development to biomarker potential.

Autor: Lu ZF; Heilongjiang Beidahuang Group General Hospital, Heilongjiang, China., Hsu CY; Department of Pharmacy, Chia Nan University of Pharmacy and Science, Tainan, Taiwan., Younis NK; Department of Pharmacy, Al-Noor University College, Nineveh, Iraq., Mustafa MA; Department of Medical Laboratory Technology, University of Imam Jaafar AL-Sadiq, Kirkuk, Iraq., Matveeva EA; Department of Orthopaedic Dentistry, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation., Al-Juboory YHO; National University of Science and Technology, Dhi Qar, Iraq., Adil M; Pharmacy College, Al-Farahidi University, Baghdad, Iraq., Athab ZH; Department of Pharmacy, Al-Zahrawi University College, Karbala, Iraq., Abdulraheem MN; College of Education, University of Anbar, Ramadi, Iraq.
Jazyk: angličtina
Zdroj: APMIS : acta pathologica, microbiologica, et immunologica Scandinavica [APMIS] 2024 Jun; Vol. 132 (6), pp. 382-415. Date of Electronic Publication: 2024 Mar 12.
DOI: 10.1111/apm.13401
Abstrakt: Rheumatoid arthritis (RA) is a multifaceted autoimmune disorder characterized by chronic inflammation and joint destruction. Recent research has elucidated the intricate interplay between gut microbiota and RA pathogenesis, underscoring the role of microbiota-derived metabolites as pivotal contributors to disease development and progression. The human gut microbiota, comprising a vast array of microorganisms and their metabolic byproducts, plays a crucial role in maintaining immune homeostasis. Dysbiosis of this microbial community has been linked to numerous autoimmune disorders, including RA. Microbiota-derived metabolites, such as short-chain fatty acids (SCFAs), tryptophan derivatives, Trimethylamine-N-oxide (TMAO), bile acids, peptidoglycan, and lipopolysaccharide (LPS), exhibit immunomodulatory properties that can either exacerbate or ameliorate inflammation in RA. Mechanistically, these metabolites influence immune cell differentiation, cytokine production, and gut barrier integrity, collectively shaping the autoimmune milieu. This review highlights recent advances in understanding the intricate crosstalk between microbiota metabolites and RA pathogenesis and also discusses the potential of specific metabolites to trigger or suppress autoimmunity, shedding light on their molecular interactions with immune cells and signaling pathways. Additionally, this review explores the translational aspects of microbiota metabolites as diagnostic and prognostic tools in RA. Furthermore, the challenges and prospects of translating these findings into clinical practice are critically examined.
(© 2024 Scandinavian Societies for Pathology, Medical Microbiology and Immunology.)
Databáze: MEDLINE
Externí odkaz: